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Abstract 
The use of bio-polymers as stabilising agents for iron oxide-based negative magnetic resonance imaging (MRI) 
contrast agents has become popular in recent years, however the wide polydispersity of biologically-derived and 
commercially available polymers limits the ability to produce truly tuneable and reproducible behaviour, a major 
challenge in this area. In this work, stable colloids of iron oxide nanoparticles were prepared utilising precision-
engineered bio-polymer mimics, poly(2-acrylamido-2-methylpropane sodium sulfonate) (P(AMPS)) polymers, 
with controlled narrow polydispersity molecular weights, as templating stabilisers. In addition to producing 
magnetic colloids with excellent MRI contrast capabilities (r2 values reaching 434.2 mM-1s-1 at 25 °C and 23 
MHz, several times higher than similar commercial analogues), variable field relaxometry provided unexpected 
important insights into the dynamic environment of the hydrated materials, and hence their exceptional MRI 
behaviour. Thanks to the polymer’s templating backbone and flexible conformation in aqueous suspension, 
nanocomposites appear to behave as “multi-core” clustered species, enhancing interparticle interactions whilst 
retaining water diffusion, boosting relaxation properties at low frequency. This clustering behaviour, evidenced 
by Small-angle X-ray scattering, and hence relaxometric response, was fine-tuned using the well-defined 
molecular weight polymer species with precise iron to polymer ratios. By also showing negligible haemolytic 
activity, these nanocomposites exhibit considerable potential for MRI diagnostics. 
Introduction 
Superparamagnetic iron oxide nanoparticles (SPIONs) have been a major research focus for a number 
of years, with applications ranging catalysis, environmental remediation, magnetically triggered 
reactions, cell labelling and bioseparation, biosensing, magnetic resonance imaging (MRI), and 
magnetic hyperthermia therapy.1–7 Their diverse applications stem from their unique size-dependent 
magnetic properties, which are tuneable thanks to their (relatively) straight-forward synthesis and 
surface modification.8 Interest in their use as MRI contrast agents has been steady over the past few 
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decades thanks to their biocompatibility and clinical application. As a useful non-invasive imaging tool, 
MRI is valuable in the diagnosis and monitoring of disease. Its potency can be enhanced through the 
application of contrast agents (CAs), which boost MRI signal contrast by decreasing indigenous water 
proton relaxation times through close molecular interactions, described in detail by the Solomon, 
Bloembergen and Morgan (SBM) equations.9–11 So-called positive CAs, usually based on paramagnetic 
Gd3+ chelates such as Magnevist® or Dotarem®, predominantly accelerate longitudinal relaxation times 
(T1), producing hyperintense signal. Negative CAs, on the other hand, principally enhance transverse 
relaxation times (T2), and are typically composed of stabilised superparamagnetic iron oxide 
nanoparticles, for example Feridex®, Resovist®, and Sinerem®, and provide regions of hypointense 
signal.12–15  
Although Gd3+-based CAs have traditionally been more popular clinically due to the 
‘brightened’ images they can provide, their use has been increasingly associated with significant risks 
such as nephrogenic systemic fibrosis (NSF), particularly towards patients with renal insufficiency, and 
more recently have been reported to accumulate in the brain.16,17 Whilst ‘uncoated’ iron oxide 
nanoparticles have been shown to exhibit low levels of toxicity, particles stabilised with a biocompatible 
polymer have been found to be relatively non-toxic. For example, commercially-available dextran 
coated superparamagnetic iron oxide nanoparticles, Ferumoxtran-10, were demonstrated to be non-
toxic to human monocyte macrophages at concentrations as high as 1 mg/ml.18 Iron oxide based MRI 
contrast agents have been widely used clinically for imaging the gastrointestinal tract, colon, liver, 
spleen, and lymph nodes.10,19–21 Although their clinical MRI use in recent years has decreased (with 
some negative contrast agents being removed from the market), there remain a number of iron oxide 
particle-based products in active clinical use, including Lumirem® (for imaging the GI tract) and 
Feraheme® (a treatment for anaemia).13,15,22 They additionally remain popular in research due to their 
unique properties which make them useful for applications such as targeted magnetic hyperthermia, 
drug delivery, cell tracking, and MRI contrast enhancement.23–28 
Recent years have seen a significant amount of research towards high performance MRI CAs 
exploiting the tuneable properties of nanoparticles.9,29–32 Excellent colloidal stability, magnetic 
properties, and well hydrated and biocompatible surfaces are the key characteristics of high performing 
nanostructured contrast agents. Advances in both the synthesis of the magnetic iron oxide core, and the 
functionalisation of the particle surface, has led to a series of magnetic particle-based contrast agents 
with strong and tuneable MRI signal.33–37 Polymeric stabilisation of negative contrast agents can be 
carried out through (covalently or non-covalently) associating polymers (e.g. polyethylene glycol or 
dextran) on iron oxide particle surfaces after their preparation, or through the in situ incorporation of a 
stabilising polyelectrolyte during nanoparticle preparation.19,38–41 The latter technique has proven 
successful in the preparation of contrast agents with excellent colloidal stability and strong contrast 
enhancement, due to the templating behaviour of some polymer species. For example, DNA, 
poly(sodium-4-styrene) sulfonate, and heparin, have been used to stabilise Fe3O4 and CoFe2O4 particles 
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following this approach, generating exceptionally high relaxation behaviour.29,42,43 Key to the strong 
contrast enhancement reported in these works was the negatively charged polymers used, whose 
backbones offered sites at which the ferritic nanoparticles could seed and grow, acting as a templating 
species, as well as colloidal stabilisers. This templating behaviour is responsible for increased magnetic 
dipole-dipole interactions between neighbouring particles, thereby boosting their relaxation response 
due to increased anisotropy.30,43 Whilst the control of particle interaction using templating polymers is 
an intriguing approach to tuneable contrast agents, commercially-available polymers generally suffer 
from high polydispersity and poorly controlled molecular weight distributions. This can detrimentally 
impact reproducibility, as well as provide poor control over the vital interparticle interactions of 
produced composites, affecting tunability of contrast agent performance.  
Recently, carefully controlled molecular weight heparin-mimicking polymers, poly(2-
acrylamido-2-methylpropane sodium sulfonate) (P(AMPS)), and their nanovesicle counterparts, have 
been produced and demonstrated excellent biocompatibility and low haemolytic activity.44,45 Herein, 
we aim to exploit these controlled molecular weight linear P(AMPS) polyelectrolytes as stabilising and 
templating agents to produce families of stable aqueous iron oxide nanocomposites. These low 
polydispersity polymers, with controlled numbers of negative sulfonate groups, provide regulation of 
the templating of magnetic cores at these seeding sites, offering the opportunity for the production of 
contrast agents with precisely tuneable interparticle interactions and hence MRI contrast behaviour. The 
proton relaxation enhancement capabilities, at single field and variable field strengths, and haemolytic 
activity of these composites are assessed towards new families of biocompatible and tuneable MRI 
contrast agents.  
Experimental 
All chemicals were used as supplied. FeCl2·4H2O (≥99.0 %), FeCl3·6H2O (97 %), ammonium 
hydroxide (BioUltra 1M), and Xanthan gum (from Xanthomonas campestris) were purchased from 
Sigma-Aldrich Ltd. Defibrinated sheep’s blood, and Triton-X 100 (≥ 98.0 %, molecular biology grade) 
were purchased from VWR, UK. Sodium 2-acrylamido-2-methylpropane sulfonate (AMPS® 2405, 50 
wt% in water) was donated by Lubrizol. Thermal initiator, 2,2′-azobis[2-methyl-N-((2- 
hydroxyethyl)propionamide] (VA-086, 98%) was obtained from Wako Chem. 2-(((butylthio)-
carbonothioyl)thio)-2-methylpropanoic acid (BDMAT) was synthesized using previous literature 
conditions.44 Ultrapure water was collected from an Elga PureLab system operated at 15.0 MΩ.  
 
Physical and Structural Characterisation 
Transmission electron microscopy (TEM) images were obtained on a Jeol JEM-1200 microscope,  
120 kV, operated with a beam current of 80 mA; images were captured using a Gatan Orius 11-
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megapixel camera. Samples were prepared by deposition and drying of nanoparticle samples (20 µL of 
stock stable magnetic fluid suspensions) onto formvar-coated 300-mesh copper TEM grids (EM 
Resolutions). Diameters were measured using ImageJ software version 1.8; average values were 
calculated by counting a minimum of 100 particles, with error derived from standard deviation. 
Magnetically aligned samples were dried in the presence of a parallel permanent magnetic field (2250 
Gauss).  
Hydrodynamic particle size and zeta potential measurements were determined by dynamic light 
scattering (DLS) using a Malvern Zetasizer Nano ZS instrument. A 4 mW He-Ne 633 nm laser module 
was used, and scattered light was measured at 173° (back scattering). The attenuator and position were 
selected automatically by the instrument and particle sizes reported as the average of at least 4 
measurements, with error derived from standard deviation. 
Small-angle X-ray scattering (SAXS) measurements were performed using a Xenocs Xeuss 2.0 
equipped with a micro-focus Cu Kα source collimated with scatterless slits providing a 0.8 mm diameter 
beam. Samples measured were stable aqueous washings which were loaded into 1 mm path length 
borosilicate glass capillaries. SAXS patterns were recorded using a Pilatus 300K detector with a pixel 
size of 0.172 mm × 0.172 mm. The sample to detector distance was calibrated using silver behenate 
(AgC22H43O2) providing a value of 2.481(5) m, providing an effective scattering vector, Q, range of 





Where 2θ is the scattering angle and λ is the X-ray wavelength. Data were collected for 4 hours at  
25 ℃. A radial integration of the 2D scattering profile was performed using FOXTROT software and 
the resulting data corrected for the absorption, sample thickness and background.46 Finally, the 
scattering intensity was then rescaled to absolute intensity using glassy carbon as a standard.47 SAXS 
data were analysed using model-dependent analysis implemented within SasView software 
(www.sasview.org).48 A model describing a fractal aggregate of spherical particles was used, as has 
been described in detail elsewhere.49 The scattering length density (SLD) defining the ‘scattering 
power’ of a material, is defined as the sum of X-ray scattering lengths, bi, of N atoms within a given 







The SLD of a material can also be calculated using the bulk density, ρ, atomic molar mass, Mi and 











Throughout the fitting procedure, the SLD of water and iron oxide nanoparticles were calculated as 
9.47×10-6 Å-2 and 41.1×10-6 Å-2, respectively, and held constant. Based on nanoparticle dispersity 
observed by DLS and TEM, a polydispersity was applied to the nanoparticle radius as a Schultz 
distribution and held at a value of 0.2. All other parameters were permitted to vary throughout the fitting 
procedure. 
Fourier transform infrared (FTIR) spectra were acquired using a Bruker Alpha FTIR 
spectrometer. A total of 128 scans were collected for solid samples after drying. Raman spectra were 
collected using a Renishaw Raman inVia microscope with a 633 nm He-Ne excitation laser (0.76 mW 
when operated at 10 % power). Magnetisation measurements were carried out in the range −15 kOe to 
15 kOe using a Quantum Design Physical Property Measurement System Vibrating Sample 
Magnetometer (VSM). Measurements (emu g-1) are based on the total mass of the solid sample, this 
will include any contribution in mass of the non-magnetic polymer. Powder X-ray diffraction was 
performed using a Stoe Stadi-P diffractometer with a molybdenum (Mo) X-ray source (50 kV and 30 
mA), λ = 0.7093 Å. Two-theta scan range was 2–40.115 ° at a step size of 0.495 ° and 5 seconds per 
step. Sample holder was a transmission sample holder and samples were prepared using STOE zero 
scattering foils.  
Room temperature (295 ± 5 K) 57Fe Mössbauer spectroscopy was performed using a SeeCo 
W302 spectrometer (SeeCo Inc., USA) operated in constant acceleration mode. Samples were prepared 
for measurement by mixing the freeze dried powder with sucrose using a pestle and mortar, to form a 
paste, which was then mounted in a 2.1 cm coin shaped absorber. Samples were mounted in 
transmission geometry, with a 57Co in Rh foil as the source of the 14.4 keV γ-rays. Velocity calibration 
was performed by recording a reference spectrum from a 10 μm thick foil of αFe, also at room 
temperature. All spectra were folded and baseline corrected using cubic spline parameters derived from 
fitting the αFe calibration spectrum, following a protocol implemented in the Recoil analysis 
program50,with spectra least-squares fitted using the ‘centre-of-gravity’ method, in which Voigtian 
lineshapes (representing Gaussian distributions of Lorentzian lines) were used in all samples.51 
Characterisation of Relaxometric Behaviour 
Measurement of 1H NMRD profiles was performed on a Stelar Spinmaster FFC2000 1T instrument in 
the range of 0.01–20 MHz Larmor frequency at two different temperatures (25 °C and 37 °C). The 
temperature was controlled using a Stelar VTC-91 airflow heater, equipped with a copper-constantan 
thermocouple; the temperature calibration in the probe head was carried out using a Delta OHM digital 
thermometer, with an absolute accuracy of 0.5 °C. Fast field cycling (FFC) relaxometry was used to 
determine the longitudinal relaxation decay over a range of relaxation fields (0.01–40 MHz). A set of 
24 relaxation interval values (tau) allowed description of the spin-lattice decay curves for each 
relaxation field. A standard fitting algorithm (mono-exponential relaxation decay curve) allowed the 
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evaluation of the relative longitudinal relaxation rate (R1 = 1/T1), which was converted to relaxivity 
using Equation (3). 
Measurement of r1 and r2 values at a fixed field strength were carried out using an Oxford 
Instruments MQC+ benchtop NMR analyser with a resonant frequency of 23 MHz operated 25 °C and 
37 °C. For the measurement of T1, the standard inversion-recovery method was employed with a typical 
90° pulse calibration of 250 µs with 4 scans per experiment; for T2, the Carr-Purcell-Meiboom-Gill 
(CPMG) method was used with 4 scans per experiment. A minimum of 3 different concentrations of 
stable nanoparticle samples were prepared and relaxation time measured for each sample. r1 and r2 
relaxivity values were calculated from curves plotted of R1 (1/T1, s-1) or R2 (1/T2, s-1) vs. [Fe] 
concentration (mM, as measured by ICP-OES) and analysis of the slope of the line of best fit for each 
sample, with error measured from measuring a minimum of 3 separately prepared batches of samples.  
An ISA Jobin Yvon Ultima 2C Inductively Coupled Plasma-Optical Emission 
simultaneous/sequential spectrometer (ICP-OES) running at 1 KW power with a 40.68 MHz 
radiofrequency Argon plasma. Plasma gas flow was 14 L min-1. Nebuliser pressure was 2.6 bar at 1 mL 
min-1 sample flow rate. The spectral line for iron was measured at 259.940 nm. Samples were digested 
for ICP-OES using hot nitric acid and diluted in ultrapure water prior to analysis. Concentrations as 
measured by this technique were used to normalize all relaxation data according to Equation (3).  
Preparation of poly(2-acrylamido-2-methylpropane sulfonic acid (P(AMPS) 
The preparation of poly(2-acrylamido-2-methylpropane sulfonic acid (P(AMPS)), was carried out as 
detailed by Bray et al.44 Briefly, the chain transfer agent (CTA) BDMAT, the initiator VA-086 (from 
stock solution at 20.0 mg mL−1), and the monomer AMPS were combined with phosphate buffer tablet 
solution (0.5 mL), and sodium hydroxide (2.5 mg, 6.3 × 10−2 mmol) in a flask and sealed with a rubber 
septum. The relative quantities of CTA, initiator, and monomer were adjusted according to the desired 
degree of polymerisation (see Table S1). The solution was deoxygenated by bubbling through with 
nitrogen for 10 minutes, and the flask was then placed in a temperature controlled oil bath at the desired 
temperature (90 °C), for the duration of time required to reach nearly full conversion (∼2 hours). At the 
end of the reaction, the mixture was cooled to room temperature and then opened to the atmosphere. 
The quoted number average molecular weight (Mn,SEC) and dispersity (Đ) values of synthesized 
polymers were determined by conventional calibration using Agilent GPC/SEC software (see Table S1 
for further detail). 
Preparation of poly(2-acrylamido-2-methylpropane sulfonic acid (P(AMPS)) Stabilised Iron 
Oxide Nanoparticles 
Three different synthetic polymers were used, each of a different molecular weight  
(Mn,SEC = 8,100, 17,600, or 41,300 g mol-1), and different molar total [Fe]:[polymer] ratios used, as 
shown in Table 1. The synthetic P(AMPS) was dissolved in 10 mL ultrapure water, and the solution 
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was subsequently degassed by bubbling with N2 for 20 mins. Separately, FeCl2·4H2O and FeCl3·6H2O 
(varied total concentration according to Table 1 but maintained at a 1:2 molar ratio) was dissolved in 
50 mL ultrapure water which had already been degassed by bubbling with N2 for 20 mins (final 
concentrations provided in Table S2, SI). The P(AMPS) solution was added to the Fe2+/3+ solution with 
the N2 atmosphere maintained. NH4OH (1 M) was added in 0.5 mL aliquots until the pH was measured 
to be in the range 9–10. The reaction was stirred at 40 °C for 2 hours. The resulting black/brown 
precipitate was washed with ultrapure water using centrifugation until pH neutral. The neutral washings 
were retained for DLS, TEM and relaxometric analysis. 
Characterisation of Haemolytic Behaviour 
Defibrinated sheep blood (2 mL) was divided between two 1.5 mL Eppendorf tubes (1 mL each) and 
centrifuged at 4500 g/8200 RPM in a mini spin Eppendorf centrifuge for 1 minute. The supernatant was 
removed and replaced with 800 µL phosphate buffered saline (PBS), in which the pellet was 
resuspended using sonication. This was repeated a minimum of 5 times, until the supernatant became 
colourless. The red blood cell suspension was diluted 1:150 (by volume) in PBS. Samples A–E were 
diluted in ultrapure water to make concentrations of 0.5 mg mL-1, 0.1 mg mL-1, 0.05 mg mL-1, and 0.01 
mg mL-1. 20 µL of each suspension was added to 380 µL of diluted red blood cells making final 
concentrations of 10, 2, 1, and 0.2 µg mL-1. Negative controls of 20 µL PBS and ultrapure H2O, and a 
100 % positive control of 1 % Triton-X in PBS was prepared. The diluted red blood cell mixtures were 
incubated at 37 °C for 1 hour. All samples were prepared in triplicate; values provided as mean of 
triplicates, with error derived from standard deviation. Particle blood mixtures were separated by 
centrifugation for 5 minutes before 250 µL of the supernatant was removed and transferred to a 96 well 
plate and the absorbance measured across the range 350–700 nm using a Molecular Devices 
SpectraMax Plus 384 plate reader. The average peak max value for the PBS negative control value was 
subtracted from the nanoparticles peak max values and divided by the average Triton-X positive control 
value to give % haemolysis. 
Results and Discussion 
Iron oxide nanoparticles stabilised with P(AMPS) polymer were prepared using an in-situ co-
precipitation technique, as described in the Experimental Section. Briefly, P(AMPS) of three different 
number average molecular weights (Mn,SEC values of 8,100, 17,600, or 41,300 g mol-1 with Đ of 1.10, 
1.16 and 1.51, respectively) were initially prepared and characterised using size exclusion 
chromatography (Figure S1 and Table S1, Supporting Information) using a previously published 
approach.44 Stabilised iron oxide nanoparticles were produced by the co-precipitation of Fe3+ and Fe2+ 
salts (at a molar ratio of 2:1) in the presence of the P(AMPS) polymers, initiated by the addition of 
ammonium hydroxide (Figure 1). In order to probe the effect of nanoparticle seeding density along the 
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polymer chain lengths on MRI contrast enhancement performance, composites were prepared with 
varied total [Fe]:[P(AMPS)] molar ratios of 100:1, 2,500:1 and 6,250:1, using P(AMPS) with a Mn,SEC 
of 8,100 g mol-1 to produce samples A, B, and C respectively (Table 1 and Figure 1). In order to probe 
the impact of increasing polymer molecular weight, and thus chain length, on particle seeding density, 
and corresponding MRI behaviour, P(AMPS) stabilised iron oxide nanoparticles were also prepared 
using different polymer chain lengths at a constant [Fe]:[P(AMPS)] molar ratio of 6,250:1 (samples D, 
and E, using polymers with Mn,SEC 17,600, and 41,300 g mol-1, respectively, Table 1 and Figure 1).   
Table 1. Molar ratios used during preparation of poly(2-acrylamido-2-methylpropane) sulfonate (P(AMPS)) 
stabilised iron oxide nanoparticles and resulting characterisation data.   













A 100:1 8,100 255.7±11.0 
[0.347] 
-25.7±7.5 12.6±3.2 71.8 
B 2,500:1 8,100 142.8±33.4 
[0.370] 
-13.2±2.1 12.9±2.8 70.8 
C 6,250:1 8,100 127.3±5.6 
[0.319] 
-23.5±1.7 11.0±2.4 72.8 
D 6,250:1 17,600 167.4±10.4 
[0.292] 
-20.7±1.7 13.9±5.3 70.9 
E 6,250:1 41,300 105.2±15.1 
[0.298] 
-15.3±1.2 12.8±3.2 71.7 
a Total initial concentration of reagents (see Table S2 for more information); b Mn,SEC is number average molecular 
weight of the P(AMPS) as measured using aqueous size exclusion chromatography (SEC); c hydrodynamic 
diameter (dhyd), zeta potential (ζ-pot) and polydispersity index (PDI) of aqueous colloids measured using dynamic 
light scattering, with the mean of 4 measurements given (error represents the standard deviation);  d dcore is the 
average particle size calculated by measuring >100 particles as imaged using transmission electron microscopy 





Figure 1. Schematic representation of the preparation of poly(2-acrylamido-2-methylpropane) sulfonate 
(P(AMPS)) stabilised iron oxide nanoparticles, with different polymer molecular weights (Mn,SEC = 8,100, 17,600, 
or 41,300 g mol-1) and molar [Fe]:[P(AMPS)] ratios, as shown in Table 1.  
Physical and Structural Characterisation 
Transmission electron microscopy (TEM) of P(AMPS) stabilised colloids showed aggregates of 
discrete particles with mean core diameters ranging 11.0–13.5 nm (Figure 2); sizes (Table 1) were 
within error of one other and not impacted by varying [Fe]:[P(AMPS)] ratio. Nanoparticles 
demonstrated alignment parallel with an applied magnetic field (2250 Gauss field applied during sample 
deposition, Figure S2, SI), behaviour attributed to the templating properties of the sulfonate backbone 






Figure 2. Transmission electron microscopy images of P(AMPS) stabilised iron oxide nanoparticles, labelled 
according to Table 1 (dcore = 11.0 ± 2.4; 13.9 ± 5.3; 12.8 ± 3.2; 12.9 ± 2.8; 12.6 ± 3.2 nm for samples A–E, 
respectively). Scale bar 100 nm. Insets show high magnification images of corresponding samples, scale bar 50 
nm. 
Aqueous hydrodynamic diameters (dhyd) as measured by dynamic light scattering (DLS) (Table 1) were 
in the range 106–256 nm. These values were significantly larger than core particle sizes as measured 
by TEM, as expected and previously observed, due to the presence of hydrogen bonding and van der 
Waals forces associated with the polymer stabilisation of the colloids.30,42 The dhyd values obtained are 
larger than similarly prepared iron oxide nanoparticles (for example, heparin-stabilised Fe3O4 particles 
which demonstrated dhyd of ~40 nm for dcore 9.0 nm nanoparticles),30 indicative of larger aqueous 
clusters of nanocomposites herein. It is notable that the measured dhyd values do not appear to correlate 
to the size of the P(AMPS) polymer chains, likely due to the low concentrations of the measured 
samples, and high degree of cross-linking and interactions between neighbouring particles. It is 
important to note that as the measurements were carried out on stable suspensions following copious 
washing procedures resulting in different concentrations for each sample, the dhyd values obtained by 
DLS cannot be directly compared with one another, and thus no trends can be assigned. Differences in 
hydrodynamic sizes observed are likely due to the differences in polymer and particle concentrations 
leading to differences in their cross-linking and Brownian motion behaviour, a well-known 
phenomenon.53,54 The impact of the concentration of a suspension of nanoparticles and specifically the 
observed dhyd is also well documented.55,56 The polydispersity index (PDI) quantifies the broadness of 
distribution of dhyd and is used to estimate the polydispersity and homogeneity of a colloidal sample. 
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Despite the cross-linking that one would expect from the presence of the polymer species in these 
nanocomposites, PDI values within the range 0.292–0.370 are indicative of their moderate 
monodispersity. Zeta potential (ζ-pot) measurements showed all samples to be negatively charged, due 
to iron oxide particle surface hydroxyl groups (confirmed by IR, vide infra), as well as the negatively 
charged P(AMPS) stabiliser. 
Small-angle X-ray scattering (SAXS) was performed on aqueous suspensions of the stabilised 
particles in order to gain further insight into the colloidal conformation adopted by these nanostructures 
in suspension. SAXS patterns obtained for all samples show similar trends; the lack of an observable 
Guinier region within the achievable Q range indicates the formation of relatively large colloidal 
suspensions in all cases, limiting the capability of SAXS to provide information describing the overall 
size of the aggregates formed by this system (Figure 3). In order to extract structural information from 
these SAXS patterns, parameters of a model describing the aggregation of primary spherical particles 
into a fractal-like cluster were fit to the experimental data, as has been previously been performed with 
similar systems.57 A detailed description of this model has been reported previously.49 Briefly, the 
fractal dimension represents the self-similarity of the aggregate. Here, we interpret this as a measure of 
the degree of clustering of individual iron oxide nanoparticles, where the radius of the clustered 
aggregate is described by the correlation length. 
 
Figure 3. Small-angle X-ray scattering (SAXS) data (points) for aqueous suspensions of P(AMPS) stabilised 
aggregates of iron oxide nanoparticles A–E with corresponding fits (lines) to models describing fractal-like 
clusters of spherical particles. 
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The parameters obtained from these fitting procedures are displayed in Table 2. In all cases, the 
radii are similar to those determined by TEM. Comparing samples A and B, as the ratio of 
[Fe]:[P(AMPS)] increased, an initial increase in fractal dimension can be observed accompanying a 
decrease in the correlation length. This indicates the particles compact into smaller, more highly 
clustered aggregates. When the [Fe]:[P(AMPS)] ratio is further increased (sample C), a swelling of the 
aggregate diameter can be observed along with a decreased clustering of iron oxide nanoparticles. This 
suggests an optimum ratio of nanoparticles to P(AMPS) is required to produce the most highly clustered 
aggregates. When considering the polyelectrolyte nature of P(AMPS), we propose that electrostatic 
repulsion between polymer chains is not countered by the low relative nanoparticle concentration in 
sample A, leading to swelling described by the larger correlation length and decreased fractal 
dimension. Similarly, sample C was prepared at the highest [Fe]:[P(AMPS)] ratio in this series. In this 
case, we propose that the capacity of the polymers to stabilise the iron oxide nanoparticles has been 
exceeded, potentially leading to electrostatic repulsion between nanoparticles. As the Mn of P(AMPS) 
is increased at a constant [Fe]:[P(AMPS)] ratio (samples C, D and E), a decrease in the correlation 
length can be observed. This suggests that an increase in Mn of P(AMPS) increases the stabilising effect 
on the nanoparticles leading to the formation of smaller aggregates. Interestingly, the fractal dimension 
initially increases then appears to stabilise close to the maximum value observed for sample B. This 
suggests that iron oxide nanoparticles partition amongst the available P(AMPS) at an apparently optimal 
compactness. 
Table 2. Structural parameters obtained through fitting of SAXS data of aqueous suspensions of P(AMPS) 
stabilised aggregates of iron oxide nanoparticles to a model describing fractal-like clusters of spherical particles. 
Quoted errors represent the standard error associated with the fitted parameter. Values marked with * were held 













A 0.8 ± 0.01 70 ± 1 0.2* 2.90 ± 0.01 335 ± 15 
B 1.9 ± 0.01 62 ± 1 0.2* 3.47 ± 0.03 85 ± 1 
C 1.6 ± 0.01 64 ± 1 0.2* 2.98 ± 0.01 170 ± 3 
D 0.7 ± 0.01 83 ± 1 0.2* 3.30 ± 0.09 101 ± 6 
E 1.5 ± 0.01 69 ± 1 0.2* 3.32 ± 0.05 80 ± 2 
 
Vibrating sample magnetometry measured between −15 kOe and 15 kOe exhibited typical 
superparamagnetic behaviour for all samples, with no magnetic hysteresis, and magnetisation values 
(Ms) in the range 70.9–72.8 emu g-1 (see Table 1 and Figure S3, SI). Room temperature (295 ± 5 K) 57Fe 
Mössbauer spectroscopy (Figure 4a) produced spectra comprising magnetically spilt sextets, 
characteristic of particles magnetically blocked on the Mössbauer timescale (approx. 1 ns). Best fits to 
the spectra were obtained using the model independent ‘Centre of Gravity’ method (Fock and Bogart 
et al. 201658) to evaluate α, the numerical proportion of Fe atoms in a magnetite-like environment, with 
Voigtian line shapes found to provide the best fit to the spectrum.51 The mean value of α for all samples 
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is ca. 0.11 with a standard deviation of 0.03 (Figure 4b and Table S3), which is indicative of maghemite 
rich iron oxide cores, with some magnetite character. Significant differences in the shape of the spectra 
are observed that correlate to both the amount and length of the P(AMPS) polymer used within the 
synthesis. Values obtained for the mean static hyperfine field of A–E are summarized in Table S3, SI. 
For samples A, B and C – across which the iron to polymer ratio increases (see Figure 1 and Table 1) – 
we see significant changes in both the mean static hyperfine field, <H>, as well as in the distribution, 
P(H) (Figure 4c). As the ratio of iron increases, <H> decreases from 409 kOe to 375 kOe, which we 
suggest is a result of the increasing frustration of the cores due to structural confinements associated 
with the increasing amount of iron within the particle, and which is likely to cause clustering of the 
cores leading to a corresponding alignment along a magnetic easy axis.  
 
Figure 4. a) Room temperature 57Fe Mössbauer spectra of dried powder samples mixed with sucrose (points) and 
best fits to the observed spectra (lines) obtained using the ‘Centre of Gravity’ method. All best fits were obtained 
using Voigtian lines (Gaussian distributions of Lorentzian lines); b) Comparison of the best fit values of spectra 
α, the numerical proportion of Fe atoms in a magnetite environment, for the five samples with corresponding 
uncertainty values obtained for each spectrum represented by error bars; c) Hyperfine field distribution (P(H)) of 
each of the room temperature spectra shown in (a).   
As the length of P(AMPS) increases between samples C to E, we see a slight restructuring of the cores 
within these clusters, indicated by the slight increase in the mean hyperfine field, and which we suggest 
gives the iron oxide cores more freedom to re-orientate, which in turn reduces the amount of frustration 
in the system. 
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Raman spectroscopy of P(AMPS) stabilised iron oxide nanoparticles featured a large peak at 
670 cm-1 and shoulder at 702 cm-1 indicating the A1g modes of magnetite and maghemite respectively 
(Figure S4, SI).59,60 A broad peak at 368 cm-1 represents the T2g mode of maghemite, and another at 494 
cm-1, attributed to the Eg mode of maghemite.59,60 The presence of a mixture of magnetite and 
maghemite phases is consistent with room temperature 57Fe Mössbauer spectroscopy analysis. Powder 
X-ray diffraction (P-XRD) confirmed the characteristic cubic structure of maghemite, with reflections 
at 13.8°, 16.2°, 19.6°, 25.5°, and 27.8° readily indexed to the (220), (311), (400), (511), and (440) planes 
of the cubic lattice inverse spinel type iron oxides (Figure S5, SI).61 Based on the combined evidence 
provided by P-XRD, Raman, and 57Fe Mössbauer spectroscopy, it is clear that the iron oxide cores of 
these nanocomposites are a mixture of both magnetite (Fe3O4) and maghemite (γ-Fe2O3) phases, which 
is typical for materials produced in this way, due to their closely related crystallographic structures, and 
since magnetite readily oxides to maghemite.51,58,62 The average composition of the nanoparticles is 
approximately 89 % maghemite and 11 % magnetite, from which it follows that the iron oxide cores of 
this nanocomposite are a magnetite/maghemite (Fe3O4/ γ-Fe2O3) mixture.   
Infrared (IR) spectroscopy confirmed the presence of the stabilising P(AMPS) on the 
maghemite nanoparticles (Figure S6, SI). The stretches between 3600–3000 cm-1 (representing OH 
stretching vibrations from surface hydroxyl groups and physisorbed water groups), and the stretch at 
650–500 cm-1 (correlating to the Fe–O stretch) are observed for the P(AMPS) stabilised nanoparticles.52 
The stabilised nanoparticles also exhibited stretches at 1370–1340 cm-1 and 1080–1030 cm-1, indicative 
of the O=S=O and C=S stretching vibrations, respectively, of functional groups on the P(AMPS) 
chains.52 
Relaxometry Studies 
Nuclear magnetic dispersion (NMRD) analysis is a variable field relaxometry technique which is useful 
in the analysis of magnetic contrast agents.6,29,30,36 It measures the longitudinal proton relaxation rate 
enhancement (r1) of a colloidal system at multiple frequencies, providing insight into relaxation 
properties and the dynamic local environment of water nearby a contrast agent species. Such behaviour 
is influenced by the magnetic properties of a particle and coupled magnetic interactions with one another 
and their surroundings. The water relaxation rate enhancement per mM concentration of contrast agent, 





Where R1,2,obs is the observed relaxation rate of the agent in aqueous suspension (R1,2 = 1/T1,2, where T1 
is the longitudinal relaxation time and T2 is the transverse relaxation time of water protons), R1,2,sol is 
the relaxation rate of the unaltered solvent system (i.e. in the absence of contrast agent) and [CA] is the 
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mM concentration of the contrast agent in suspension, as measured using inductively coupled plasma 
optical emission spectroscopy (ICP-OES).  
NMRD analysis of aqueous suspensions of the P(AMPS) stabilised iron oxide nanoparticles is 
displayed in Figure 5a. At magnetic field strengths of B0 > 0.2 T (or > 10 MHz), relaxation behaviour 
is dominated by Curie relaxation, a phenomenon resulting from the induction of a local magnetic field 
through the application of an external field on the superparamagnetic nanoparticles, and the resultant 
interactions between water protons and these local magnetic fields.63 Relaxation at these field strengths 
is determined primarily by the strength of the magnetic moments and water diffusional correlation times 
around magnetic particle cores and therefore tends to correlate to the particle size, dcore.30,63 As dcore is 
similar for samples A–E (Table 1), the NMRD profiles converge at > 10 MHz, as seen in Figure 5a. At 
lower frequencies (< 10 MHz), the Curie component of relaxation is lost and Néel relaxation (the 
random fluctuation of magnetic moments) dominates. The seminal model by Roch, Muller, and Gillis 
first detailed proton relaxation induced by superparamagnetic particles, with profiles that featured a low 
field plateau (or dispersion), a mid-field peak (νmax), and a decrease in longitudinal relaxivity at higher 
field strengths.63 In their model, as the diameter of the magnetic nanoparticles increased, νmax shifted to 
lower frequencies and low field r1 relaxivities (at 0.01 MHz) increased, indicative of an increase in the 
magnetocrystalline anisotropy linked to particle size. For the samples produced herein, νmax is shifted 
to lower frequencies, and r1 is greatly increased at low Larmor frequencies. As the core sizes of the 5 
samples do not differ significantly (Table 1), this observed behaviour is not attributable to this well-
modelled size-related increase in the magnetocrystalline anisotropy. Such behaviour, which diverges 
from the well-accepted superparamagnetic model, has been previously observed for clustered materials 
formed from core-shell,64 and multi-core iron oxide nanoparticles,65 as well as for iron oxide 
nanoparticles seeded along biopolymers, such as denatured DNA strands,43 and fatty acids.66  
 
Figure 5. a) 1H NMRD profiles of longitudinal relaxivity (r1) of P(AMPS) stabilised iron oxide nanoparticles in 
0.1 % Xanthan gum, measured at 37 °C; b) Longitudinal relaxivity (r1) at 0.01 MHz of P(AMPS) stabilised iron 
oxide in 0.1 % Xanthan gum, measured at 25 °C and 37 °C. Each data point represents a single measurement.  
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A model for the effect of agglomeration of superparamagnetic particles on r1 has been 
developed by Gillis et al., demonstrating aggregation-induced changes in low frequency dispersion and 
νmax in NMRD profiles.67 In that work, it was noted that agglomeration resulted in an overall decrease 
in longitudinal relaxivity, due to reduced total surface area of particles available for important, diffusive 
interactions with surrounding water protons. However, this is clearly not the case herein for samples 
A–E, where absolute r1 values at low frequency remain extremely high (Figure 5b). This observed 
strong relaxation rate enhancement is attributed to the hydrated nature of the polymer-stabilizing 
species, which facilitates water access to all available particle surface areas, overcoming these 
previously observed reductions in relaxivity. Bio-heparin stabilized iron oxide particles have similarly 
exhibited enhanced r1 relaxivities at low frequencies, behaviour attributed to increased anisotropy 
arising from interactions between particles clustered along the polymer backbone.30 Such high low field 
relaxivities are supported by Lévy et al., who established that the intrinsic magnetic properties of multi-
core or clustered nanoparticles results in large relaxivity enhancements at low field strengths due to 
slowing of the dynamics of the magnetic moments (i.e. progressive blocking of Néel fluctuations due 
to local magneto-anisotropy).65,68 Clustering-enhanced relaxation effects have also been observed for 
multi-core iron oxide nanoparticles, including ‘nanoflower’ structures (composed of an assembly of 
magnetic cores).65,69 Herein, cross linking between neighbouring P(AMPS) polymer chains result in the 
formation of effective “multi-core like” nanostructures in suspension, and supports the observed strong 
low field relaxivities, which closely resemble the multi-core model proposed by Lévy et al. 
In our samples, this phenomenon is likely due to the propensity for colloidal polymers to adopt 
different energetically-favourable conformations (brush, mushroom, coil, etc.) when in aqueous 
suspension.70,71 This dynamic behaviour may bring the iron oxide cores (associated with negative 
polyelectrolyte backbones) close together, resulting in this “multi-core like” behaviour, whilst the 
hydrophilic nature of the polymers ensures excellent water diffusivity, avoiding reduced relaxivities as 
a result of agglomeration and hence restricted water access, as had been observed by Gillis et al.67 
Indeed, the templating nature of the polyelectrolyte species and nanoparticle seeding behaviour it 
encourages may serve to impact the adopted conformation of the polymer chains, with nanoparticles 
shown to have profound effects on the motion and molecular conformation of polymers in polymer-
nanoparticle composites.72,73  
This dynamic behaviour appears to impact the low frequency r1 of the samples prepared herein 
(Figure 5b). More dynamic and flexible samples, possessing higher amounts and longer chain lengths 
of polymers possess the highest low field relaxivities (e.g. samples A and E), whereas samples with 
high densities of iron oxide particles and smaller polymer chain lengths (e.g. sample C) have lower low 
frequency r1 values, due to their inherently lower dynamic flexibility, a well-accepted phenomenon in 
aqueous systems. Herein, increased flexibility enhances hydration and clustering of the iron oxide 
particles, making it more effective and hence resulting in the high r1 relaxation enhancement. This 
behaviour is supported by the SAXS data discussed previously, in which the fractal-like aggregation of 
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iron oxide particles is concurrent with the idea that there are varying degrees of ‘clustering’ with these 
multi-core like structures leading to differences in the distance between magnetic cores, and 
interparticle interactions which are known to boost relaxation properties. Similar trends in NMRD 
relaxation were observed at 25 °C (Figure S7, SI). 
Table 3. Summary of r1 and r2 relaxometric properties of P(AMPS) stabilised iron oxide nanoparticle samples 
(A–E) measured at a single field strength (23 MHz) and at temperatures of 25 °C and 37 °C. 
Sample r2 (mM-1s-1) r1 (mM-1s-1) r2/r1 
25 °C 37 °C 25 °C 37 °C 25 °C 37 °C 
A 331.5 ± 13.3 312.4 ± 31.4 40.1 ± 1.6 41.0 ± 1.5 8.3 7.6 
B 363.4 ± 30.8 318.5 ± 21.9 34.6 ± 1.4 33.1 ± 2.9 10.5 9.6 
C 434.2 ± 59.4 386.2 ± 32.2 42.7 ± 1.9 41.2 ± 0.2 10.2 9.4 
D 431.0 ± 25.4 386.4 ± 17.4 39.9 ± 1.7 39.3 ± 1.5 10.8 9.8 
E 367.1 ± 18.7 318.5 ± 19.4 40.3 ± 3.3 39.9 ± 3.3 9.2 8.0 
Values presented are the mean and standard deviation of the measured relaxivities of a minimum of 3 replicates 
for each sample (A–E). 
The transverse relaxivities (r2) of aqueous colloids of the P(AMPS) stabilised iron oxide 
nanoparticles were additionally measured at a single field strength of 23 MHz to assess their efficacy 
as negative contrast agents (Table 3). Unlike longitudinal relaxation (measured in NMRD analysis), 
transverse relaxation is not proportional to Larmor frequency, as the mechanism for relaxation is reliant 
on the dephasing of the proton spins and is dominated by outer sphere interactions. r2 relaxivities 
showed general correlation with the cluster size, with smaller aggregates (following fractal dimension 
according to SAXS, as previously discussed) demonstrating lower r2 relaxivities due to their overall 
lower magnetic moment. All samples demonstrated extremely high r2 values, ranging  
331–435 mM-1s-1 at 25 °C, far exceeding that of clinical analogues such as Feridex® (r2 = 120 mM-1s-1 
at 25 °C and 20 MHz).15 At 37 °C, r2 values for all samples are slightly reduced, due to the thermal 
activation of water molecules and its subsequent impact on the diffusional correlation time around the 
particle cores, a well-documented phenomenon.74 High r2/r1 ratios, ranging 8.3–10.8 at 25 °C, indicated 
their strong potential as negative CAs.  
Haemolytic Activity 
Haemocompatibility is crucial for in vivo bio-applications of nanomaterials, particularly if the 
nanocomposite is to come into contact with blood through intravenous clinical administration.75,76  Due 
to their poor colloidal stability, uncoated iron oxide nanoparticles have a high tendency for 
agglomeration under physiological conditions, and have shown considerable damage to red blood cells 
and their membranes, resulting in haemolysis.77,78,79 To quantitatively determine the blood compatibility 
of the nanocomposites described herein, a widely used haemolysis assay was carried out, adapted from 
methods detailed in the literature.45 Briefly, the release of haemoglobin from ovine red blood cells was 
measured using UV-vis spectroscopy after incubation with the P(AMPS) stabilised iron oxide 
nanoparticles (Figure 6, details in Experimental Section). The percentage haemolysis was calculated 
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for different concentrations (0.2-10 µg mL-1) for each of the 5 samples, with the % haemolysis found 
to be in the range of 8.1–24.6 %. These results were found to be statistically insignificant with respect 
to the negative control of water (P >0.05), therefore demonstrating the good haemocompatibility of the 
P(AMPS) stabilised nanoparticles. The ability of a coating or stabiliser to improve the 
haemocompatibility of iron oxide nanoparticles has been well documented in the literature. For 
example, a study of polyethyleneimine (PEI) and polyethylene glycol (PEG) coated SPIONs showed 
that PEI-coated nanoparticles exhibited severe dose-dependent haemolysis due to formation of large 
aggregates in the presence of plasma, whilst a PEG coating on SPIONS prevented the formation of such 
aggregates, resulting in  no haemolytic activity.80 Likewise, a comparison between polyacrylic acid-, 
hyaluronic acid-, and chitosan-modified iron oxide nanoparticles found the chitosan- and hyaluronic 
acid-functionalised nanoparticles had superior blood compatibility, behaviour linked to their improved 
colloidal  stability.77 P(AMPS) has already been demonstrated to have excellent blood compatibility (at 
concentration ranges of 1–100 µg mL-1, showing % haemolysis 18.2–22.2 %), behaviour linked to its 
heparin-mimicking properties.45 As such, it is reasonable to link the excellent blood compatibility 
observed in the samples herein to the use of the P(AMPS) stabilising agent. However, it is important to 
note that the concentrations of P(AMPS) present within the nanocomposites prepared in this work are 
much lower than those used to determine blood compatibility of polymers alone (concentrations 
presented herein represent complete polymer-nanoparticle composites). Despite this, it is clear that there 
is sufficient polymer present to provide excellent blood compatibility. Further, it is interesting to note 
that the measured haemolysis of the clinically approved anti-coagulant heparin falls within the range 
observed for the P(AMPS) coated iron oxide nanoparticles herein (8.1–24.6 %),45 emphasising their 
potential for future safe biomedical application.  
 
Figure 6. Haemocompatibility of P(AMPS) stabilised iron oxide nanoparticles (A–E) measured as a percentage 
with 100 % positive control using 1 % Triton-X in PBS, with water and PBS as negative controls. Figure shows 




The ability of polymers to act as stabilisers as well as templating agents in the preparation of colloidal 
magnetic nanoparticles has been established in the literature in recent years. A number of works have 
produced nanocomposites with enhanced magnetic relaxation properties due, in part, to template-
mediated interparticle interactions, which have been controlled through tuning the seeding density of 
nanoparticles along polyelectrolyte backbones.29,30,43 However, despite efforts to tune relaxation 
behaviour of the nanocomposites, poor polydispersity of commercial polymers hampers the true 
reproducibility and tunability of these interesting systems, and lack insight into the colloidal behaviour 
of these interesting systems. Herein, we have utilised a precision-designed poly(2-acrylamido-2-
methylpropane sodium sulfonate) (P(AMPS)) polymer with well-defined molecular weights, to produce 
colloidal magnetic nanocomposites which form clusters of particles in aqueous suspension, thanks to 
the polymer’s controlled number of sulfonate sites guiding seeded nanoparticle growth. This means of 
control has resulted not only in magnetic nanocomposites with improved relaxometric properties, but 
has also provided insight into the unique and dynamic colloidal behaviour of this important class of 
polymer-stabilised MRI contrast agents. Through exploitation of the polymer chains’ dynamic 
flexibility in solution, as well as the density of particles associated with the polymer chains, 
nanocomposites with different degrees of colloidal clustering behaviour can be produced, which 
facilitate interparticle interactions vital for boosted proton relaxation. Variable field relaxometry 
(nuclear magnetic resonance dispersion, NMRD) allowed interpretation of these important interactions, 
revealing unexpected behaviour, in particular at low field strengths. The loss of a defined νmax and low 
field dispersion (through increased r1 in the 0.01–0.1 MHz range), correlates with relaxometric 
behaviour observed for multi-core magnetic nanoparticles previously modelled in the literature.65,68,69 
Small-angle X-ray scattering confirmed the colloidal properties of these composites in suspension – 
demonstrating the formation of multi-core clusters of nanoparticles in the samples prepared herein, with 
the degree of clustering influenced by the [Fe]:[P(AMPS)] ratio, as well as the P(AMPS) Mn, where an 
increase in chain length resulted in the formation of smaller clusters, which present high low field r1 
relaxivities. Together, this data clearly illustrates the ability to tune the degree of clustering and hence 
control the MRI behaviour of this family of contrast agents, through modulation of the important 
interparticle interactions. This work emphasises, for the first time, the necessity to carefully tune all 
aspects of reagent properties when selecting materials for the production of colloidal nanoparticles for 
medical applications. High single field r2 relaxivities (of up to r2 = 434.2 ± 59.4 mM-1s-1 at 23 MHz and 
25 °C) far exceed that of clinical analogues such as Feridex (r2 = 120 mM-1s-1 at 25 °C and 20 MHz).15 
Alongside excellent MRI contrast potential, low haemolytic activity was measured for all 
nanocomposites produced, demonstrating the good biocompatibility of the samples.  
Collectively, the results demonstrate that judicious choice of polymer, in particular considering 
polydispersity and polymer chain length, as well as carefully designed composite ratios, are of vital 
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importance in tailoring the resulting properties of produced colloidal nanocomposites, in particular for 
biomedical applications such as MRI. Precision designed polymers are ideal for such applications, 
allowing careful control not only over the well-established importance of interparticle interactions, but 
also composite flexibility and nanoparticle clustering, which we have demonstrated to play a key role 
in the resulting MRI contrast behaviour. Future work with this new family of negative MRI contrast 
agents will focus on further detailing their biological behaviour both in vitro and in vivo. 
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